ChiCTR-IIR-17013331
正在进行
/
/
/
2017-11-10
/
/
Allergic Rhinitis
Clinical Efficacy and Safety of Oral Supplement of Allium ascalonicum L. in Patients with Allergic Rhinitis
Clinical Efficacy and Safety of Oral Supplement of Allium ascalonicum L. in Patients with Allergic Rhinitis
(1) To determine the efficacy and safety of oral supplement of Allium ascalonicum L. in patients with mild-persistent allergic rhinitis (2) To compare the efficacy and safety of oral supplement of Allium ascalonicum L. to placebo in patients with mild-persistent allergic rhinitis (3) To observe the possible adverse effects of oral supplement of Allium ascalonicum L.
随机平行对照
Ⅱ期
Randomization will be performed according to computer-generated schedule as described in www.Randomization.com
/
Chiang Mai University
/
60
/
2017-11-15
2018-11-15
/
Subjects will be male and female, aged 18-60 years old who were diagnosed with mild-persistent allergic rhinitis (according to ARIA 2008 guidelines) with previous history of positive skin prick test or presence of positive skin prick test to at-least 1 allergen during screening period. They must have total nasal symptom scores (TNSS) ≥ 6 within prior 2 weeks and the score of nasal congestion must not exceed 2 (≤ 2). All subjects must be explained and clearly understand the details of this research protocol, and give their written informed consent before entering the study.；
请登录查看Subjects were excluded from the study if they had: (1) marked anatomical abnormality of nose such as nasal septum deviation, nasal polyposis, unilateral obstruction; (2) infection of respiratory tract within 2 weeks before the study; (3) use of oral or intranasal corticosteroids within 4 weeks before the study; (4) nasal surgery within 4 weeks before the study; (5) currently on immunotherapy or previously received immunotherapy within 1 year before entering the study; (6) hypersensitivity of cetirizine or ingredient of the drug; (7) hypersensitivity of Allium ascalonicum L. or chemical in Allium ascalonicum L.; (8) history of asthma, cancer, hepatic diseases (AST, ALT > 1.5 times of the upper limit of normal range) or renal disease (eGFR < 50 ml/min), heart disease (using the digoxin); (9) pregnancy or breastfeeding.；
请登录查看Faculty of Medicine, Chiang Mai University
/
新药与伴随诊断网2026-01-12
医药观澜2026-01-12
国风药业2026-01-12
三叶草生物制药2026-01-12
君实医学2026-01-12
华东医药投资者关系2026-01-12
动脉网2026-01-12
凌科药业2026-01-12
丽珠医药2026-01-12
药明康德2026-01-12
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
